Patents by Inventor Annapurna Pendri

Annapurna Pendri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20230322695
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 12, 2023
    Inventors: Haibo Liu, Laura Akullian D′Agostino, Shoshana L. Posy, Annapurna Pendri, Swanee E. Jacutin-Porte
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20230193260
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: July 27, 2022
    Publication date: June 22, 2023
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. Cacace, Jere E. Meredith, JR., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11447775
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11359197
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20220119811
    Abstract: The present disclosure relates to antisense oligonucleotides, which target Alpha-synuclein (SNCA) transcript in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder such as a synucleinopathy.
    Type: Application
    Filed: January 11, 2019
    Publication date: April 21, 2022
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Richard E. OLSON, Angela M. CACACE, Marianne Lerbach JENSEN, Jeffrey M. BROWN, Jere E. MEREDITH, JR., Annapurna PENDRI, Ivar M. MCDONALD, Martin GILL
  • OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
    Publication number: 20210371860
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of MYH7 in a target cell. The oligonucleotides hybridize to MYH7 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of hypertrophic cardiomyopathy using the oligonucleotide.
    Type: Application
    Filed: May 7, 2019
    Publication date: December 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Richard OLSON, Marianne JENSEN, Annapurna PENDRI, Brian ANDERSON, Sean Carl LITTLE, Linda Jane BRISTOW, John Ryan THOMPSON, Ron AMMAR
  • Antisense Oligonucleotides Targeting Alpha-Synuclein and Uses Thereof
    Publication number: 20210180065
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200362347
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 19, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200354720
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 12, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10221129
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John A. Bender, Robert G. Gentles, Annapurna Pendri, Alan Xiangdong Wang, Nicholas A. Meanwell, Brett R. Beno, Robert A. Fridell, Makonen Belema, Van N. Nguyen, Zhong Yang, Gan Wang, Selvakumar Kumaravel, Srinivasan Thangathirupathy, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Mallikarjuna Rao Mettu, Manoranjan Panda
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10035760
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth:
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: July 31, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180086697
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 22, 2016
    Publication date: March 29, 2018
    Inventors: John A. BENDER, Robert G. GENTLES, Annapurna PENDRI, Alan Xiangdong WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Van N. NGUYEN, Zhong YANG, Gan WANG, Selvakumar KUMARAVEL, Srinivasan THANGATHIRUPATHY, Rajesh Onkardas BORA, Shilpa Maheshwarappa HOLEHATTI, Mallikarjuna Rao METTU, Manoranjan PANDA
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9855230
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: January 2, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Makonen Belema, John A. Bender, Brett Beno, Robert G. Gentles, Guo Li, Nicholas A. Meanwell, Annapurna Pendri, Zhong Yang, Shirong Zhu
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170304239
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: September 3, 2015
    Publication date: October 26, 2017
    Applicant: ViiV Healthcare UK (No.5) Limited
    Inventors: Makonen BELEMA, John A. BENDER, Brett BENO, Robert G. GENTLES, Guo LI, Nicholas A. MEANWELL, Annapurna PENDRI, Zhong YANG, Shirong ZHU
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20160257645
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)
    Type: Application
    Filed: October 23, 2014
    Publication date: September 8, 2016
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9034882
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 19, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Annapurna Pendri, David R. Langley, Samuel Gerritz, Guo Li, Weixu Zhai, Stanley D'Andrea, Manoj Patel, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang
  • Compounds for the treatment of hepatitis C
    Patent number: 8741884
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: June 3, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Annapurna Pendri, Guo Li, Samuel Gerritz, Weixu Zhai, Paul Michael Scola, Li-Qiang Sun, Eric Mull
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8633200
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 21, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Annapurna Pendri, Guo Li, Samuel Gerritz, David R. Langley, George L. Trainor, Nicholas A. Meanwell
  • Compounds for the treatment of hepatitis C
    Patent number: 8586584
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 19, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20130231331
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Inventors: Annapurna Pendri, David R. Langley, Samuel Gerritz, Guo Li, Weixu Zhai, Stanley D'Andrea, Manoj Patel, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang